Atossa Therapeutics (NASDAQ: ATOS) deepens Z-endoxifen bet as 2025 losses widen and rare disease optionality grows
Read More 1 minute read Pharma Industry News Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1 Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA’s approval to commence Phase II… byPallavi MadhirajuDecember 17, 2023